Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of vinpocetine-containing composition in cerebrovascular diseases

A technique for vinpocetine and cerebrovascular disease, which is applied in the application of drugs for ischemic cerebrovascular disease, in the field of preparation and treatment of cerebrovascular disease, can solve the problems of neurological defect symptoms and cerebral infarction area without improving effect, and achieves an increase in the number of drugs. effective effect

Pending Publication Date: 2021-03-12
YANTAI YENEPHARMA BIOMEDICAL
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] According to the published patent (CN105311022A), in the middle cerebral artery occlusion (MCAO) cerebral ischemia-reperfusion model in rats, vinpocetine (80 mg / kg) alone and D-camphor / L-camphor were intravenously administered immediately after reperfusion Alcohol (20 mg / kg), has no effect on improving the neurological deficit symptoms and cerebral infarct size in rats after 24 hours of cerebral ischemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of vinpocetine-containing composition in cerebrovascular diseases
  • Application of vinpocetine-containing composition in cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Study on the Neuroprotective Effect of the Composition of Vinpocetine and Dxborneol

[0020] 1 Materials and methods

[0021] 1.1 Animals

[0022] Pregnant SD rats, Shanghai Sijie Experimental Animal Co., Ltd.

[0023] 1.2 Reagents and consumables

[0024] name Item No. / Lot No. manufacturer Neurobasal 21103-049 Gibco B27 17504-044 Gibco GlutaMax 2110349 Gibco CellTiter-Glo G7571 Promega Polylysine (PDL) P6407 Sigma DMEM 11995-040 Gibco Sugar-free DMEM 1763966 Gibco Pennicillin Streptomycin (P / S) 15140-122 Gibco Fetal bovine serum (FBS) 10099-141 Gibco Anaerobic tank gas control system DMS don whitley scientific Cell Culture Plate Corning 3610 / 96 well cell culture plate Corning Vinpocetine YL20181103 Shanghai Yulan Biotechnology Co., Ltd. Dexaborneol KC20171205-1-2 Jiangsu Ouwei Pharmaceutical Co., Ltd.

[0025] 1.3 Preparation of prima...

Embodiment 2

[0049] Example 2 Study on the Protective Effect of Vinpocetine and Dxborneol Composition on Focal Cerebral Ischemia-Reperfusion Injury 1

[0050] 1 Materials and methods

[0051] 1.1 Experimental animals

[0052] Sprague-Dawley (SD) rats, male, SPF grade, body weight 250-280g.

[0053] 1.2 Test drugs

[0054] Vinpocetine and Dxborneol are the same as in Example 1.

[0055] 1.3 Experimental method

[0056] 1.3.1 Preparation of focal cerebral ischemia-reperfusion model

[0057] The focal cerebral ischemia-reperfusion model in rats was established by internal carotid artery suture method. The rats under anesthesia were fastened with rubber bands on the limbs (the hind limbs were fixed above the knee joint, and the forelimbs were fixed above the wrist joint) and the head. The animal was fixed on the operating table in a supine position, and the animal shaver was used to shave from the head to the chest. Hair, alcohol to disinfect the skin. The neck was cut midline, and the ...

Embodiment 3

[0087] Example 3 Study on the Protective Effect of the Composition of Vinpocetine and Dxborneol on Focal Cerebral Ischemia-Reperfusion Injury 2

[0088] 1 Materials and methods

[0089] 1.1 Experimental animals

[0090] Sprague-Dawley (SD) rats, male, SPF grade, body weight 250-280g.

[0091] 1.2 Test drugs

[0092] Vinpocetine and Dxborneol are the same as in Example 1.

[0093] 1.3 Experimental method

[0094] The preparation of the focal cerebral ischemia-reperfusion model, the neurological deficit symptom score and the measurement method of the cerebral infarction area are the same as in Example 2.

[0095] Experimental animals were divided into vinpocetine group (3 mg / kg), dexbornol group (0.3 mg / kg), vinpocetine and dexborneol composition group (3.3mg / kg, vinpocetine: dextroborneol camphor=10:1) and the model group, a total of 4 groups. After the cerebral ischemia model was prepared, the animals were assigned to each group in a single-blind manner with equal probab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition containing vinpocetine or pharmaceutically acceptable salt thereof and dextroborneol, and an application of the composition in preparation of medicines for treating cerebrovascular diseases, especially ischemic cerebrovascular diseases.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the application of a composition of vinpocetine and d-borneol in the preparation of medicaments for treating cerebrovascular diseases, especially ischemic cerebrovascular diseases. Background technique [0002] Cerebrovascular disease (CVD) refers to brain lesions caused by various cerebrovascular diseases, and can be divided into acute cerebrovascular disease (stroke) and chronic cerebrovascular disease according to its pathogenesis process. Acute cerebrovascular diseases include transient ischemic attack, cerebral thrombosis, cerebral embolism, hypertensive encephalopathy, cerebral hemorrhage and subarachnoid hemorrhage; chronic cerebrovascular diseases include cerebral arteriosclerosis, cerebrovascular dementia, cerebral arterial Steal syndrome, Parkinson's disease, etc. Ischemic stroke (Stroke) is a general term for brain tissue necrosis caused by stenosis or occlusion of cerebral bloo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K31/045A61P9/10A61P25/00
CPCA61K31/4375A61K31/045A61P9/10A61P25/00A61K2300/00
Inventor 张正平王磊安文吉
Owner YANTAI YENEPHARMA BIOMEDICAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com